论文部分内容阅读
[目的]探讨双歧三联活菌胶囊联合莫沙必利对动力障碍型功能性消化不良(FD)患者血清胃肠激素水平的影响及疗效观察。[方法]选择动力障碍型FD患者86例,随机将其分为2组(试验组和对照组),每组均43例。试验组患者予以双歧三联活菌胶囊(420mg/次,3次/d,餐后约0.5h温水服用)联合莫沙必利(5mg/次,3次/d,餐前约0.5h口服),连用8周。对照组患者予以单纯的莫沙必利治疗,剂量、用法及疗程同试验组。观察2组患者治疗前和治疗8周后血清胃动素(MTL)和生长抑素(SS)水平的变化,并比较其临床疗效及药物不良反应。[结果]治疗8周后,2组患者血清MTL水平较治疗前明显上升,SS水平较治疗前明显下降(P<0.05或P<0.01),且试验组上升或下降程度比对照组更明显(P<0.05);同时试验组总有效率(95.35%)明显高于对照组(79.07%)(χ2=5.11,P<0.05);2组治疗期间共发生不良反应8例,其中对照组5例和试验组3例,症状较轻微,2组不良反应发生率比较差异无统计学意义(χ2=0.14,P>0.05)。[结论]双歧三联活菌胶囊联合莫沙必利治疗动力障碍型FD患者的疗效明显优于单纯的莫沙必利治疗,且安全性较好,其作用机制可能与其能升高血清MTL水平,降低血清SS水平,更有效地改善胃肠道的动力,加快胃肠道的排空密切相关。
[Objective] To investigate the effect of bifid triple viable capsule combined with mosapride on the level of serum gastrointestinal hormones in patients with functional dysfunction (FD) and its therapeutic effect. [Methods] 86 patients with FD were selected and randomly divided into two groups (experimental group and control group), 43 cases in each group. Patients in the test group were given bifidobacterium triple viable capsules (420mg / time, 3 times / d, warm water after about 0.5h) combined with mosapride (5mg / time, 3 times / d orally for about 0.5h before meals) , Used in conjunction for 8 weeks. Patients in the control group were treated with mosapride alone. The dosage, usage and course of treatment were the same as those in the test group. The changes of serum motilin (MTL) and somatostatin (SS) in two groups before and eight weeks after treatment were observed. The clinical efficacy and adverse drug reactions were compared. [Results] After 8 weeks of treatment, the serum MTL levels in two groups were significantly increased compared with those before treatment, and the level of SS was significantly lower than that before treatment (P <0.05 or P <0.01), and the level of MTL in the two groups was significantly higher than that of the control group P <0.05). The total effective rate (95.35%) in the experimental group was significantly higher than that in the control group (79.07%) (χ2 = 5.11, P <0.05) And experimental group (3 cases). The symptoms were mild and there was no significant difference in the incidence of adverse reactions between the two groups (χ2 = 0.14, P> 0.05). [Conclusion] Bifid triple viable capsule combined with mosapride treatment of FD patients with FD is superior to mosapride alone, and its safety is better, its mechanism may be related to its ability to increase serum MTL levels , Lower serum SS levels, improve gastrointestinal motility more effectively and speed up gastrointestinal emptying.